Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

S. Peters; E. Felip; U. Dafni; C. Belka; M. Guckenberger; A. Irigoyen; E. Nadal; A. Becker; H. Vees; M. Pless; A. Martinez-Marti; A. Tufman; M. Lambrecht; N. Andratschke; A. C. Piguet; M. Kassapian; H. Roschitzki-Voser; M. Rabaglio-Poretti; R. A. Stahel; J. Vansteenkiste; D. De Ruysscher

doi:10.1016/j.lungcan.2019.05.001

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A. C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R. A. Stahel, J. VansteenkisteD. De Ruysscher^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	83-87
Number of pages	5
Journal	Lung Cancer
Volume	133
DOIs	https://doi.org/10.1016/j.lungcan.2019.05.001
Publication status	Published - Jul 2019

Keywords

Non-small cell lung cancer
NSCLC
Chemotherapy
Radiotherapy
Cancer immunotherapy
Immune checkpoint inhibitors
PD-1 inhibitor
Nivolumab
Combination treatment

Access to Document

10.1016/j.lungcan.2019.05.001

Cite this

Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., Martinez-Marti, A., Tufman, A., Lambrecht, M., Andratschke, N., Piguet, A. C., Kassapian, M., Roschitzki-Voser, H., Rabaglio-Poretti, M., Stahel, R. A., ... De Ruysscher, D. (2019). Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer, 133, 83-87. https://doi.org/10.1016/j.lungcan.2019.05.001

Peters, S. ; Felip, E. ; Dafni, U. ; Belka, C. ; Guckenberger, M. ; Irigoyen, A. ; Nadal, E. ; Becker, A. ; Vees, H. ; Pless, M. ; Martinez-Marti, A. ; Tufman, A. ; Lambrecht, M. ; Andratschke, N. ; Piguet, A. C. ; Kassapian, M. ; Roschitzki-Voser, H. ; Rabaglio-Poretti, M. ; Stahel, R. A. ; Vansteenkiste, J. ; De Ruysscher, D. / Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. In: Lung Cancer. 2019 ; Vol. 133. pp. 83-87.

@article{2a8c01177e004d83b7fc7be4e145c39d,

title = "Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial",

keywords = "Non-small cell lung cancer, NSCLC, Chemotherapy, Radiotherapy, Cancer immunotherapy, Immune checkpoint inhibitors, PD-1 inhibitor, Nivolumab, Combination treatment",

author = "S. Peters and E. Felip and U. Dafni and C. Belka and M. Guckenberger and A. Irigoyen and E. Nadal and A. Becker and H. Vees and M. Pless and A. Martinez-Marti and A. Tufman and M. Lambrecht and N. Andratschke and Piguet, {A. C.} and M. Kassapian and H. Roschitzki-Voser and M. Rabaglio-Poretti and Stahel, {R. A.} and J. Vansteenkiste and {De Ruysscher}, D.",

year = "2019",

month = jul,

doi = "10.1016/j.lungcan.2019.05.001",

language = "English",

volume = "133",

pages = "83--87",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, AC, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, RA, Vansteenkiste, J & De Ruysscher, D 2019, 'Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial', Lung Cancer, vol. 133, pp. 83-87. https://doi.org/10.1016/j.lungcan.2019.05.001

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. / Peters, S.; Felip, E.; Dafni, U.; Belka, C.; Guckenberger, M.; Irigoyen, A.; Nadal, E.; Becker, A.; Vees, H.; Pless, M.; Martinez-Marti, A.; Tufman, A.; Lambrecht, M.; Andratschke, N.; Piguet, A. C.; Kassapian, M.; Roschitzki-Voser, H.; Rabaglio-Poretti, M.; Stahel, R. A.; Vansteenkiste, J.; De Ruysscher, D.

In: Lung Cancer, Vol. 133, 07.2019, p. 83-87.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

AU - Peters, S.

AU - Felip, E.

AU - Dafni, U.

AU - Belka, C.

AU - Guckenberger, M.

AU - Irigoyen, A.

AU - Nadal, E.

AU - Becker, A.

AU - Vees, H.

AU - Pless, M.

AU - Martinez-Marti, A.

AU - Tufman, A.

AU - Lambrecht, M.

AU - Andratschke, N.

AU - Piguet, A. C.

AU - Kassapian, M.

AU - Roschitzki-Voser, H.

AU - Rabaglio-Poretti, M.

AU - Stahel, R. A.

AU - Vansteenkiste, J.

AU - De Ruysscher, D.

PY - 2019/7

Y1 - 2019/7

KW - Non-small cell lung cancer

KW - NSCLC

KW - Chemotherapy

KW - Radiotherapy

KW - Cancer immunotherapy

KW - Immune checkpoint inhibitors

KW - PD-1 inhibitor

KW - Nivolumab

KW - Combination treatment

U2 - 10.1016/j.lungcan.2019.05.001

DO - 10.1016/j.lungcan.2019.05.001

M3 - Article

C2 - 31200833

VL - 133

SP - 83

EP - 87

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -